Chronos is a CNS specialist company with a high concentration of expertise in both degenerative and behavioural diseases of the brain and nervous system.
Dr Huw JonesCEO
Dr Helen KuhlmanVP Corporate Development
Clinical Accelerator conducts all phases of clinical trials for pharma, biotech and medtech companies. We have a very simple mission: to accelerate clinical development projects and to reduce their cost appreciably for our clients. We use several strategies to achieve very compact timelines in our clinical studies: - optimization of study design (only necessary outcome measures and end-points, right number of patients, optimal follow-up duration) - selection of effective investigative sites located in our region of operation. All our sites, conducting trials to the highest standards of GCP, have a large patient recruiting capacity and a proven track record of efficient timely recruitment of qualified patients. - accelerated start up (fast regulatory and IRB/EC approval times, streamlined logistics, expedited contracting, fast site activation, USA IND or EU CTA are optional in our region of operation) - effective patient enrolment and retention (dedicated department, proven region-specific patient recruitment strategies) We are specialists in effective and timely patient recruitment, and commit to achieving patient enrolment targets within fixed timelines. We routinely rescue stalled clinical trials. We are able to reduce the cost of our clinical projects significantly due to our: - flat organizational hierarchy, reasonable service rates and very modest internal overhead costs - commitment to agreed fixed budgets (rare need for change orders) - modest investigator grants and low hospital overheads in our region of operation (very large savings can be achieved in many therapeutic areas) - use of as few locations and as few investigative sites as possible without compromising patient recruitment rates (this limits set-up costs and lowers per patient cost) - short study timelines, which lead to reduced management costs - potential risk sharing (optional strategy) The cost of our studies is among the most attractive globally. We commit to our budgets and fix them for our clients.
Dr NIKOLAI NIKITINDIRECTOR
Cypralis was spun out from Selcia Ltd (Ongar, Essex) in 2013 to exploit its extensive expertise and know-how in targeting peptidyl-prolyl isomerases (known as PPIases), a large family of druggable protein targets involved in many acute and chronic diseases. Cypralis is dedicated to the discovery and development of innovative therapeutics for the inhibition of PPIases and expects to build upon its existing intellectual property estate through its own R&D activities and also through risk-sharing collaborations with pharmaceutical companies.
Mr Simon KerrCEO
Dr Michael PeelCSO
Femeda is a UK based company focused on developing a range technically ground breaking medical devices for female urinary incontinence. 698 million women worldwide are affected by incontinence, yet many existing products focus on managing and treating the symptoms of urinary incontinence, rather than the underlying cause.
Femeda is focused on the launch of Pelviva™, a unique patented disposable medical device for the treatment of female incontinence. Pelviva™, uses reactive pulse technology to strengthen weak pelvic floor muscles to prevent leaks and control urge incontinence. Pelviva™ has been shown to clinically improve bladder control in 84% of women after 12 weeks of treatment.
Mr Andrew TaskerChief Executive
Mr Colin WillisFounder
IA-Group is a strategic partner to bio-pharmacutical companies. We bring extensive therapeutic knowledge and regulatory expertise in strategic use of clinical imaging to enhance understanding of the mode of action, to increase the efficiency of clinical decisions and to accelerate drug development.
IA’s operations team leverage our global footprint and the next-generation cloud based proprietry platform Dynamika to de-risk trial execution and to ensure data quality and integrity. Our venture arm pioneer unique targeted investment and risk-sharing models to enable our clients to reach the next value inflection point faster. We fuse decades of theraputic insight and agile culture to meet today's speed and high standard of therapeutic innovation.